Comparisons of the effects of stent eccentricity on the neointimal hyperplasia between Sirolimus-eluting stent versus Paclitaxel-eluting stent

Yonsei Medical Journal

Volumn 51, Issue 6, 2010, Pages 823-831

  Kim, Byeong Keuk ^a,b   Ko, Young Guk ^b   Oh, Seungjin ^a   Kim, Jung Sun ^b   Kang, Woong Chol ^c   Jeon, Dong Woon ^a   Yang, Joo Young ^a   Choi, Donghoon ^b   Hong, Myeong Ki ^b   Ahn, Taehoon ^c   Jang, Yangsoo ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

Drug eluting stents; Intravascular ultrasonography; Restenosis

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STATISTICAL SIGNIFICANCE;

AGED; ANGIOGRAPHY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PACLITAXEL; SIROLIMUS; TUNICA INTIMA; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77957944698     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.6.823     Document Type: Article

References (18)

1. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, et al. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002;106:1788-93.
2. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
3. Lambert TL, Dev V, Rechavia E, Forrester JS, Litvack F, Eigler NL. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin. Circulation 1994;90:1003-11.
4. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104:600-5.
5. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-54.
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
7. Kaneda H, Ako J, Honda Y, Terashima M, Morino Y, Yock PG, et al. Impact of asymmetric stent expansion on neointimal hyperplasia following sirolimus-eluting stent implantation. Am J Cardiol 2005;96:1404-7.
8. Kim JS, Moon JY, Ko YG, Choi D, Jang Y, Kang WC, et al. Intravascular ultrasound evaluation of optimal drug-eluting stent expansion after poststent balloon dilation using a noncompliant balloon versus a semicompliant balloon (from the Poststent Optimal Stent Expansion Trial [POET]). Am J Cardiol 2008;102: 304-10.
9. de Jaegere P, Mudra H, Figulla H, Almagor Y, Doucet S, Penn I, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 1998;19:1214-23.
10. Nakano M, Wagatsuma K, Iga A, Nii H, Amano H, Toda M, et al. Impact of highly asymmetric stent expansion after sirolimuseluting stent implantation on twelve-month clinical outcomes. J Cardiol 2007;49:313-21.
11. Mintz GS, Weissman NJ. Intravascular ultrasound in the drugeluting stent era. J Am Coll Cardiol 2006;48:421-9.
12. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the Sirius trial. J Am Coll Cardiol 2004;43:1959-63.
13. Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J 2006;27: 1305-10.
14. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, et al. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation 2004;110:3430-4.
15. Hasegawa T, Ako J, Ikeno F, Waseda K, Suzuki Y, Honda Y, et al. Comparison of nonuniform strut distribution between two drugeluting stent platforms. J Invasive Cardiol 2007;19:244-6.
16. Opolski MP, Pracon R, Mintz GS, Weissman NJ, Mandinov L, Pregowski J, et al. Stent strut distribution at implantation and 9- month follow-up in TAXUS and bare metal stents and its effect on neointimal hyperplasia. J Am Coll Cardiol 2009;53:A9.
17. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, et al. Local determinants of thrombus formation following sirolimuseluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv 2009;2:459-66.
18. Kim U, Kim JS, Kim JS, Lee JM, Son JW, Kim J, et al. The initial extent of malapposition in ST-elevation myocardial infarction treated with drug-eluting stent: the usefulness of optical coherence tomography. Yonsei Med J 2010;51:332-8.